"Phenytoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.
| Descriptor ID |
D010672
|
| MeSH Number(s) |
D03.383.129.308.432.555.730
|
| Concept/Terms |
Phenytoin- Phenytoin
- 5,5-Diphenylhydantoin
- Fenitoin
- 5,5-diphenylimidazolidine-2,4-dione
- Diphenylhydantoin
Phenytoin Sodium- Phenytoin Sodium
- Sodium Diphenylhydantoinate
- Diphenylhydantoinate, Sodium
|
Below are MeSH descriptors whose meaning is more general than "Phenytoin".
Below are MeSH descriptors whose meaning is more specific than "Phenytoin".
This graph shows the total number of publications written about "Phenytoin" by people in this website by year, and whether "Phenytoin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phenytoin" by people in Profiles.
-
Asadi-Pooya AA, Rostaminejad M, Zeraatpisheh Z, Mirzaei Damabi N. Cosmetic adverse effects of antiseizure medications; A systematic review. Seizure. 2021 Oct; 91:9-21.
-
Quon RJ, Meisenhelter S, Adamovich-Zeitlin RH, Song Y, Steimel SA, Camp EJ, Testorf ME, MacKenzie TA, Gross RE, Lega BC, Sperling MR, Kahana MJ, Jobst BC. Factors correlated with intracranial interictal epileptiform discharges in refractory epilepsy. Epilepsia. 2021 02; 62(2):481-491.
-
Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, Ta Michael Lee M, Llerena A, Whirl-Carrillo M, Klein TE, Phillips EJ, Mintzer S, Gaedigk A, Caudle KE, Callaghan JT. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021 02; 109(2):302-309.
-
Asadi-Pooya AA. Phenytoin for neuroprotection. Lancet Neurol. 2016 08; 15(9):901.
-
Mintzer S, Miller R, Shah K, Chervoneva I, Nei M, Skidmore C, Sperling MR. Long-term effect of antiepileptic drug switch on serum lipids and C-reactive protein. Epilepsy Behav. 2016 05; 58:127-32.
-
Vasagar B, Verma BR, Dewberry RG, Pula T. Paradoxical Seizure Response to Phenytoin in an Epileptic Heroin Addict. Neurologist. 2015 Jun; 19(6):158-9.
-
Deeb S, McKeown DA, Torrance HJ, Wylie FM, Logan BK, Scott KS. Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC-MS-MS with a focus on their role in forensic cases. J Anal Toxicol. 2014 Oct; 38(8):485-94.
-
Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov; 96(5):542-8.
-
Riviello JJ, Claassen J, LaRoche SM, Sperling MR, Alldredge B, Bleck TP, Glauser T, Shutter L, Treiman DM, Vespa PM, Bell R, Brophy GM. Treatment of status epilepticus: an international survey of experts. Neurocrit Care. 2013 Apr; 18(2):193-200.
-
Wang SP, Mintzer S, Skidmore CT, Zhan T, Stuckert E, Nei M, Sperling MR. Seizure recurrence and remission after switching antiepileptic drugs. Epilepsia. 2013 Jan; 54(1):187-93.